Novo Nordisk 's blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released Tuesday.
Ozempic specifically lowered the risk of kidney disease progression, major cardiac events and death by 24% in diabetic patients with chronic kidney disease compared to a placebo.
Chronic kidney disease would be a big additional treatment opportunity for Ozempic: Roughly 40% of people with diabetes also have the condition.
The trial, called FLOW, first started in 2019 and followed roughly 3,500 patients with diabetes and moderate to severe chronic kidney disease.
Last year, a late-stage trial on Wegovy showed that it cut the risk of heart attacks and strokes by 20%.
Persons:
Ozempic, –, Eli Lilly
Organizations:
Novo Nordisk, U.S
Locations:
Riedisheim, France, Europe, Danish, Novo